Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Naloxone + oxycodone prolonged release tablets vs oxycodone

Adverse events · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction

Naloxone + oxycodone prolonged release tablets showed no clear difference in adverse events compared with oxycodone prolonged‐released tablets (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 1.01 [0.87, 1.18]
3 studies · 362 participants
Low

Naloxone + oxycodone prolonged release tablets vs oxycodone

Serious adverse eventsg · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction

It is very uncertain whether naloxone + oxycodone prolonged release tablets changes serious adverse eventsg compared with oxycodone prolonged‐released tablets (very low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 0.68 [0.44, 1.06]
3 studies · 362 participants
Very low